We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+39.65%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$2.91B
AUM Growth
+$647M
Cap. Flow
-$57.9M
Cap. Flow %
-1.99%
Top 10 Hldgs %
34.16%
Holding
142
New
8
Increased
32
Reduced
31
Closed
11

Top Buys

Rank Stock Value
1
TWLO icon
Twilio
TWLO
+$68.4M
2
XYL icon
Xylem
XYL
+$29M
3
ROP icon
Roper Technologies
ROP
+$21.6M
4
VMC icon
Vulcan Materials
VMC
+$16.1M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$13.4M

Top Sells

Rank Stock Value
1
SEND
SendGrid, Inc.
SEND
+$77.4M
2
LOXO
Loxo Oncology, Inc
LOXO
+$38.4M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$36.4M
4
PANW icon
Palo Alto Networks
PANW
+$19.8M
5
SAGE
Sage Therapeutics
SAGE
+$19M

Sector Composition

Rank Sector Weight
1 Healthcare 46.61%
2 Technology 21%
3 Consumer Discretionary 9.25%
4 Industrials 6.6%
5 Communication Services 3.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGNX icon
76
MacroGenics
MGNX
$245M
$8.72M 0.3%
+485,000
New +$8.38M
ARYAU
77
DELISTED
ARYA Sciences Acquisiton Corp. Unit
ARYAU
$8.28M 0.28%
800,000
– –
EXR icon
78
Extra Space Storage
EXR
$32.2B
$8.15M 0.28%
80,000
– –
THOR
79
DELISTED
Synthorx, Inc. Common Stock
THOR
$8.15M 0.28%
400,000
– –
RARX
80
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$8.06M 0.28%
359,900
-28,100
-7% -$604K
VIRX
81
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$7.25M 0.25%
170,442
+105,715
+163% +$2.4M
UROV
82
DELISTED
Urovant Sciences Ltd.
UROV
$6.72M 0.23%
669,000
– –
WVE icon
83
Wave Life Sciences
WVE
$1.13B
$6.62M 0.23%
170,400
– –
RGEN icon
84
Repligen
RGEN
$8.2B
$6.5M 0.22%
110,000
– –
XENE icon
85
Xenon Pharmaceuticals
XENE
$6.28B
$6.31M 0.22%
620,691
+196,258
+46% +$1.66M
XNCR icon
86
Xencor
XNCR
$1.48B
$6.3M 0.22%
203,000
– –
ADVM
87
DELISTED
Adverum Biotechnologies
ADVM
$6.01M 0.21%
114,658
– –
XLRN
88
DELISTED
Acceleron Pharma
XLRN
$6M 0.21%
128,900
– –
ETTX
89
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
$5.78M 0.2%
879,541
– –
KNSA icon
90
Kiniksa Pharmaceuticals
KNSA
$6.11B
$5.76M 0.2%
319,000
– –
ORTX
91
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$4.83M 0.17%
27,000
– –
VRTX icon
92
Vertex Pharmaceuticals
VRTX
$124B
$4.78M 0.16%
26,000
-197,000
-88% -$36.4M
GYRE icon
93
Gyre Therapeutics
GYRE
$668M
$3.75M 0.13%
61,714
+28,914
+88% +$1.86M
AVTX icon
94
Avalo Therapeutics
AVTX
$1.03B
$3.5M 0.12%
+208
New +$3.11M
FENC icon
95
Fennec Pharmaceuticals
FENC
$345M
$3.49M 0.12%
720,000
– –
VBIV
96
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$3.46M 0.12%
61,667
– –
BEP icon
97
Brookfield Renewable
BEP
$9.7B
$2.51M 0.09%
147,305
-45,975
-24% -$725K
FHB icon
98
First Hawaiian
FHB
$3.42B
$2.45M 0.08%
94,000
– –
ABB
99
DELISTED
ABB Ltd
ABB
$2.43M 0.08%
129,000
+2,000
+2% +$38.7K
TERP
100
DELISTED
TerraForm Power, Inc
TERP
$2.4M 0.08%
175,000
-5,000
-3% -$61.5K
2 3
4
5 6

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.03B AUM 40.55% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return

Eventide Asset Management's Q1 2019 Portfolio in Review

As of Q1 2019, Eventide Asset Management held 142 positions worth $2.91B, up 29% from $2.26B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Eventide Asset Management's Q1 2019 filing shows 8 new, 32 increased, 31 reduced and 11 closed positions. Its largest new stake was Xylem: 397,000 shares worth $31.4M. The largest sale was SendGrid, Inc., an estimated $77.4M.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 43% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Eventide Asset Management's largest Q1 2019 buy was Xylem: 397,000 shares worth $31.4M.
  • Eventide Asset Management added most to Twilio in Q1 2019, an estimated $68.4M increase.
  • Eventide Asset Management's biggest Q1 2019 reduction was Vertex Pharmaceuticals, cutting an estimated $36.4M.
  • Eventide Asset Management fully exited SendGrid, Inc. in Q1 2019, selling an estimated $77.4M.
  • Eventide Asset Management's ten largest holdings make up 34% of its $2.91B portfolio in Q1 2019.
  • Eventide Asset Management opened 8 new positions and closed 11 in Q1 2019.
  • Eventide Asset Management's portfolio value rose 29% quarter-over-quarter to $2.91B.

Based on Eventide Asset Management's 13F filing for Q1 2019, filed 15 May 2019.